Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [1985]
News [3223]
Articles [134]
Editorials [3]
Conferences [121]
elearning [18]
ASH 2021: Azacitidine with venetoclax and magrolimab shows high response rates in patients with newly diagnosed older/unfit or high-risk AML
ASH 2021: Azacitidine with venetoclax and magrolimab shows high response rates in patients with newly diagnosed...
ASH 2021: Venetoclax in combination with gilteritinib demonstrates molecular clearance of FLT3 mutation in relapsed/refractory FLT3-mutated AML
ASH 2021: Venetoclax in combination with gilteritinib demonstrates molecular clearance of FLT3 mutation in...
Finding new tools for leukaemia treatment
Finding new tools for leukaemia treatment
ASH 2021: New drug combo may improve family-donated stem cells as blood cancer treatment
ASH 2021: New drug combo may improve family-donated stem cells as blood cancer treatment
ASH 2021: Research identifies potential approach to mitigate CAR T-cell therapy toxicity
ASH 2021: Research identifies potential approach to mitigate CAR T-cell therapy toxicity
ASH 2021: Drug combination found to keep chronic lymphocytic leukaemia in young patients in remission for several years
ASH 2021: Drug combination found to keep chronic lymphocytic leukaemia in young patients in remission for several...
ASH 2021: Bispecific antibody shows 75% response rate at highest dose levels in heavily pretreated multiple myeloma
ASH 2021: Bispecific antibody shows 75% response rate at highest dose levels in heavily pretreated multiple myeloma
ASH 2021: Older adults at high risk for multiple myeloma precursor condition may benefit from screening
ASH 2021: Older adults at high risk for multiple myeloma precursor condition may benefit from screening
ASH 2021: Trial identifies five-drug combo for ‘ultra high risk’ bone marrow cancer
ASH 2021: Trial identifies five-drug combo for ‘ultra high risk’ bone marrow cancer
ASH 2021: Statistical models predict benefit of non-intensive AML therapy
ASH 2021: Statistical models predict benefit of non-intensive AML therapy

More from ecancer

Register with ecancer to receive our newsletter

Register here

Explore patient resources at ecancerpatient

Visit site

Find out more about ecancer and the work we do

About ecancer

Support ecancer's work by making a donation